



Case Report

Case report and characterization of a Brazilian family with a rare hemoglobin variant—Hb Maputo

Eliana Abreu Santos^{ID}, Renato Sampaio Carvalho^{ID},
Luciana Serrão Wermelinger^{ID} *

Faculdade de Farmácia da Universidade Federal do Rio de Janeiro (FF UFRJ), Rio de Janeiro, RJ, Brazil

ARTICLE INFO

Article history:

Received 5 May 2023

Accepted 12 February 2024

Available online 17 April 2024

Introduction

Hemoglobin (Hb) is the main protein in red blood cells, composed by a tetrameric structure with 2 α and 2 β chains. Dysfunctions in this molecule result in a group of diseases called hemoglobinopathies comprising Hb variants and thalassemia. More than 1000 hemoglobin variants have been identified so far, affecting approximately 7 % of the world population.¹ Common and rare Hb variants were found in the Brazilian population, but usually with no clinical repercussions. Hb Maputo is caused by the point mutation c.142G>T, leading to the amino acid exchange p.Asp47Tyr of the β chain. It was first described in 1983 in a patient from Maputo –Mozambique with a severe anemia condition associated with HbS.² Later, in 1991, a US family was identified carrying the heterozygous mutation with no clinical nor laboratory impact.³ In Brazil, Hb Maputo was reported in 2013 in 2 newborn individuals and their mothers from Minas Gerais, all of

them in heterozygosity and with no clinical and laboratory consequences.⁴ The HBB:c.9T>C variant is a silent mutation, commonly found in the healthy population, without any pathological relationship.^{5,6} This Hb variant does not affect glycated hemoglobin A1c (HbA1c) and does not impair Diabetes mellitus diagnosis and monitoring.⁷ This work aimed to describe an in-depth study with hematological, biochemical, and molecular analysis of a family from Duque de Caxias, the nearby city of Rio de Janeiro-Brazil, bearing Hb Maputo and HBB:c.9T>C variant.

Methods

Blood samples from four individuals of the same family, a 3 m/o male, 35 y/o father, 31 y/o mother, and 27 y/o paternal aunt, were collected by vacuum venipuncture and used for biochemical laboratory tests performed by Labmax Plenno (Labteste, Buenos Aires, Argentina), Hb-HPLC (Variant I Express, Bio-Rad, Japan), vitamin B12, folic acid, alkaline Hb electrophoresis and osmotic fragility curve (OFC) with and without incubation at 37 °C for 24 h by spectrophotometry. Molecular analyzes were performed for the detection of α thalassemia (deletions α 3.7 kb, α 4.2 kb and α -SEA) by multiplex polymerase chain reaction (PCR) (T100 Thermal Cycler,

* Corresponding author at: Laboratório de Análises Clínicas da Faculdade de Farmácia (LACFar), Departamento de Análises Clínicas e Toxicológicas, Faculdade de Farmácia, Universidade Federal do Rio de Janeiro, Rio de Janeiro, RJ, Brazil.

E-mail address: lwerrao@pharma.ufrj.br (L.S. Wermelinger).
<https://doi.org/10.1016/j.htct.2024.02.025>

2531-1379/© 2024 Associação Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier España, S.L.U. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

BioRad, Singapura) and by automated Sanger DNA sequencing for detection of β thalassemia-associated point mutations IVS1–1, IVS1–5, IVS1–6, IVS1–110 and CD 39 in the HBB gene (region chr11: 5,226,658–5,227,244, Genome Browser GRCh38/hg38). All participants in this study signed the informed consent form approved by the research ethics committee of Clementino Fraga Filho University Hospital (protocol 5.737.364).

Case report

The infant and his parents were referred to the Laboratory of Clinical Analysis of the Faculty of Pharmacy/UFRJ (LACFAR/UFRJ) to analyze a variant Hb detected in newborn screening tests for congenital diseases. The child and the father presented previous exams describing the presence of a variant Hb by Hb-HPLC, with a similar retention time to HbA₂, in a single peak representing 35–40 % of total Hb. The case investigation was initiated with the hematological and biochemical examination of the child's father, mother, and paternal aunt. The infant's complete blood count presented a slight increase in RBC and diminished levels of MCH, whereas the RDW was increased (18 %), associated with an augmented resistance in the OFT. The evaluation of iron metabolism showed diminished serum levels of this ion and transferrin saturation index, indicating an iron deficiency anemia, which could influence RDW and OFT outcomes (Table 1). However, the investigation performed in the father's samples, bearing the same Hb variant, did not show iron deficiency but OFT resistance was maintained. Biochemical analysis revealed increased levels of unconjugated bilirubin and GGT, however with LDH and reticulocyte values between the healthy range, probably due to hepatic function impairment. The infant's erythrocyte hematoscopy revealed rare Echinocytes, Schistocytes and Elliptocytes, possibly caused by iron deficiency. In the father's hematoscopy, some Stomatocytes and the presence of rare macroplatelets were observed. The mother's HbA_{1c} was slightly altered, above the reference value. The other laboratory evaluations of the family and molecular analysis of alpha and beta thalassemia, showed results within the reference value, as well as the Hb-HPLC profile (Table 1). Analysis of Hb-HPLC chromatograms was performed for the entire family for evaluation and comparison with previous data. The presence of 34.5 % variant Hb was confirmed for the infant, with a retention time (RT) of 3.82 s, superimposed on HbA₂. In addition to the child, only the father showed variation in the Hb profile, with 41 % of the Hb variant and RT of 3.80 s (Figure 1A). Based on the chromatographic profile, percentage of variant Hb found and RT, candidate Hb were identified as HbG Copenhagen, HbE or Hb Maputo (BIORAD, <https://hemoglobins.bio-rad.com/pages/chromatogram.aspx?plaid=2&metid=4>). Then, alkaline Hb electrophoresis was performed, demonstrating similar migration to HbS, in heterozygosis (HbAS), for the father and the child, discarding HbE, which presents a distinct migration pattern (Figure 1B). Finally, the sequencing of a fragment of the beta-globin gene was carried out to identify the Hb variant. Figure 1C shows the sequencing electropherograms of the infant (Figure 1C.1), who presented the HBB:c.142G>T

mutation in heterozygosis compatible with Hb Maputo, as well as his father. The laboratory parameters evaluated for the mother did not show any change when compared to the reference value, but the gene sequencing showed a mutation at position c.9T>C, which characterizes HBB:c.9T>C (Figure 1C.2), already described for not promoting laboratory and clinical repercussions, being considered a silent mutation. It is noteworthy that the sequenced fragment discarded the presence of HbS, HbG Copenhagen and HbE for all investigated family members. Aunt did not show mutations in the analyzed fragment (data not shown).

Discussion

The investigation of this clinical case began with the anomalous chromatographic profile of the infant and father, who had the Hb variant eluted together with HbA₂ in concentrations greater than 35 %. According to Giambonal et al.,⁸ HbA₂ levels greater than 8 % correspond to a variant Hb eluting at the same position. According to the characteristics presented by the laboratory tests, the possible candidates for variant Hb would be HbG Copenhagen, HbE or Hb Maputo. HbE was ruled out by the electrophoretic mobility of the variant Hb, similar to the mobility of HbS. Characteristics of a group of Hb known as "HbS like", is that Hb has electrophoretic migration similar to the HbS pattern, but with different mutations. The solubility test has an inconclusive result: it does not have the characteristic precipitation of HbS, but it does not show a negative result. According to the database of globin variant genes (<https://globin.bx.psu.edu/>), both Hb Maputo and G Copenhagen present mutation in codon 47 of beta-globin, namely: HbG Copenhagen p.Asp47Asn HBB: c.142G>A and Hb Maputo p.Asp47Tyr HBB: c.142G>T. Only after sequencing, it was possible to identify the mutation present in heterozygosis in the beta-globin chain fragment of the child and his father, corresponding to Hb Maputo. In addition, the mother's electropherogram (Figure 01.C.2) showed a heterozygous mutation in codon 2 (HBB: c.9T>C p.His2His) corresponding to HBB:c.9T>C a silent mutation, without clinical repercussions and wild-type genotype for the Maputo variant. The paternal aunt did not present mutations in the analyzed fragment. Hb Maputo presents the substitution of the polar negatively charged amino acid Aspartic Acid by Tyrosine, with an aromatic and relatively non-polar side chain, at codon 47 of the beta-globin chain, located on the outside surface of the molecule.² Literature data describe that Hb Maputo has alkaline electrophoretic mobility similar to HbS, in addition to normal molecular stability and affinity for oxygen.² A fact that corroborates the scenario without clinical repercussions in the presence of this Hb variant, in heterozygosis, but the same cannot be said when in association with HbS. Marinucci et al. first described Hb Maputo in a 2-year-old child in association with HbS, who had severe anemia (Hb 8.5 g/dL), a palpable spleen and a marked clinical status, presenting hematoscopy with abnormal morphology in the red series (Target cell and Anisocytosis).² A profile was also found in our investigated patient. In our findings, the father, who presented simple heterozygosity for Hb Maputo, did not present any clinical symptoms, which leads us to suggest that the presence of only this Hb variant

Table 1 – Summary of laboratory data of the proband and his family members.

	Infant	Reference	Father	Reference	Mother	Paternal aunt	Reference
Age	3 months	3–6 months	35 years	Male adult	31 years	27 years	Female adult
WBC (x 10 ⁹ /L)	12.6	6.0–17.5	6.2	5.0–10.0	9.6	5.5	5.0–10.0
RBC (x 10 ¹² /L)	4.61	3.1–4.5	4.68	4.5–5.9	4.48	4.65	4.0–5.2
Hb (g/dL)	11.5	9.5–13.5	13.8	13.5–17.5	14.2	13.6	12.0–16.0
Hct (%)	34.4	29–42	40.6	41–53	40.8	38.8	36–46
MCV (fL)	75	74–108	87	80–100	91	84	80–100
MCH (pg)	24.9	25–35	29.6	25–34	31.7	29.3	25–34
MCHV (g/dL)	33.4	30–36	34	31–37	34.8	35.1	31–37
RDW (%)	18.3	11–15	14.4	11–15	14.2	14.2	11–15
Platelets (x 10 ⁹ /L)	307	200–500	128	140–400	343	183	140–400
Ret (%)	0.43	0.5–2.5	0.5	0.5–2.5	1.83	0.5	0.5–2.5
B12 (pg/mL)	756	210–980	571	210–980	662	1034	210–980
FA (ng/mL)	20	> 5.38	7.7	> 5.38	7.1	12.9	> 5.38
SF (ng/mL)	44.1	22–320	209.4	22–320	103.1	99.4	10–291
SI (ug/dL)	23	40–100	98	65–170	82	61	50–170
TIBC (ug/dL)	311	150–400	279	250–450	322	309	250–450
TS (%)	7.4	20–50	35.1	20–50	25.5	19.7	20–50
TB (mg/dL)	0.24	≤ 1.2	1.62	≤ 1.2	0.37	0.94	≤ 1.2
IB (mg/dL)	0.11	≤ 0.8	1.13	≤ 0.8	0.22	0.57	≤ 0.8
LDH (U/L)	465	≤ 500	316	200–480	262	302	200–480
AST (U/L)	28	16–62	21	11–39	11	25	10–37
ALT (U/L)	12	26–55	22	11–45	10	11	10–37
ALP (U/L)	157	75–390	73	27–100	59	72	27–100
GGT (U/L)	17	12–122	67	7–58	28	29	5–39
Glucose (mg/dL)	ND	70–99	89,0	70–99	99	ND	70–99
Fructosamine (umol/L)	ND	ND	240,0	205–285	250	ND	205–285
Insulin (uUI/mL)	ND	–	7,8	2,6–24,9	8,1	ND	2,6–24,9
HbA1c (%)	ND	–	5,3	Normal: <5,7 %	5,8	ND	Normal: <5,7 %
Alpha-thalassemia	Negative	Negative	Negative	Negative	Negative	Negative	Negative
Beta-thalassemia	Negative	Negative	Negative	Negative	Negative	Negative	Negative
OFT	Resistant	Normal	Resistant	Normal	Normal	Normal	Normal
IOFT	Resistent	Normal	Resistent	Normal	Normal	Normal	Normal
Hb A (%)	63.3	96.0–98.0	58.0	> 95.0	91.1	96.8	> 95.0
Hb A ₂ (%)	ND	2–4	ND	< 3.5	2.7	3.2	< 3.5
Hb F (%)	1.2	< 5.0	1.0	< 2.0	1.2	0	< 2.0
Hb unknown (%)	35.4*	–	41.0*	–	ND	–	ND
Solubility Test	ND	–	Inconclusive	Negative	Negative	ND	Negative

WBC: white blood cells; RBC: red blood cells; Hb: hemoglobin; Hct: hematocrit; MCV: mean corpuscular volume; MCH: mean corpuscular hemoglobin; MCHC: mean corpuscular hemoglobin concentration; RDW: red cell distribution width; Ret: reticulocyte count; B12: B12 Vitamin; FA: Folic Acid; SF: serum ferritin; SI: serum iron; TIBC: total iron binding capacity; TS: transferrin saturation; TB: total bilirubin; IB: indirect bilirubin; LDH: lactate dehydrogenase; AST: Aspartate Aminotransferase; ALT: Alanine Aminotransferase; ALP: Alkaline Phosphatase; GGT: Gamma-Glutamyltransferase; DM: Diabetes Mellitus; Alpha-thalassemia: $\alpha^{3.7 \text{ kb}}$, $\alpha^{4.2 \text{ kb}}$ and $\alpha^{-\text{SEA}}$ Deletions; Beta-thalassemia: IVS1–1, IVS1–6, IVS1–110 and CD 39 mutations; OFT: Osmotic Fragility Test; IOFT: Incubated (37 °C/24 h) Osmotic Fragility Test; Hb A, Hb A₂ and Hb F: Hemoglobins A, A₂ and Fetal quantification by cationic exchange HPLC respectively. *Later identified as Hb Maputo. ND: not determined.

in heterozygosity can be silently manifested. As the incidence of HbS is high in Brazil, it is crucial to identify and register Hb Maputo due to the risk of causing symptoms of severe anemia in individuals with associated genotypes (HbS/Hb Maputo).² Iron deficiency anemia observed in the infant could favor resistance to hemolysis in the OFT, but the father did not present such nutritional deficiency and his result remained resistant, suggesting that the observed profile could be associated with the variant Hb. In hemoglobinopathies (thalassemia and HbS) and iron deficiency anemia, there is an increase in resistance to hemolysis due to the increased ability to incorporate a greater volume of water by red blood cells and remain intact in hypertonic solutions.⁹ This laboratory finding is interesting for Hb Maputo since it broadens the characterization of this hemoglobinopathy. Finally, the mother, who

has a wild-type genotype for Hb Maputo and a heterozygote for HBB:c.9T>C, despite having normal glucose metabolism, the result for HbA1c was slightly above the reference value. Her other results were normal, including OFT, Hb-HPLC results and alkaline Hb electrophoresis. The HBB:c.9T>C mutation has been described to not effect on the quantification of HbA1c in ion exchange HPLC during the investigation of diabetic patients.⁷ Given the low frequency worldwide on Hb Maputo and the scarce existing literature and HBB: c. 9T>C, the findings of this family become relevant and can contribute to a better characterization of hemoglobin variants, helping to a better laboratory diagnosis and helping public health policies. Consequently, the expansion of the frequency record of rare Hb in our country sheds light on the possible association of that rare Hb with other Hb variants with high prevalence in Brazil.




Figure 1–(A.1) Hb-HPLC of the infant showing unknown Hb with the same retention time of HbA2. (A.2) Hb-HPLC of the father showing unknown Hb with the same retention time of HbA2. (A.3) Hb-HPLC of the mother showing normal profile; (B) Electrophoresis of hemoglobins at pH 8.0. 1: Hb A (mother); 2: Hb AS; 3: Hb A/Maputo (infant); 4: Hb SC; 5: Hb AS; 6: Hb A/Maputo (father). (C) Electropherogram of the globin gene: (C.1) Sequencing of the beta-globin gene revealed a mutation in the codon 47 ($\beta 47$ Asp>Tyr-HBB: c.142G>T) in heterozygosis corresponding to Hb Maputo, (C.2) Sequencing of the beta-globin gene revealed a mutation in the codon 2 ($\beta 2$ His>His; HBB: c.9T>C) in heterozygosis, a silent variant.

Despite this real possibility of interaction between Hb Maputo with other hemoglobin variants, only Hb Maputo has been previously described in association with HbS with severe anemia.²

Despite the association of mutations in HBB gene of Thalassaemic patients with silent mutation HBB: c.9T>C no additional pathological effect was detected.⁶

Conflicts of interest

The authors declare no conflicts of interest.

Acknowledgments

This work was financially supported by Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro (FAPERJ), Brazil. We thank all the members of the Laboratory of Clinical Analysis of the School of Pharmacy (LACFar, UFRJ, Brazil) and HORIBA for their technical support.

REFERENCES

1. Rosenfeld LG, Bacal NS, Cuder MAM, Silva AGD, Machado ÍE, Pereira CA, et al. Prevalence of hemoglobinopathies in the Brazilian adult population: national health survey 2014-2015. *Rev Bras Epidemiol.* 2019;22(Suppl 02):E190007. <https://doi.org/10.1590/1980-549720190007.supl.2>. PMID: 31596378.
2. Marinucci M, Boissel JP, Massa A, Wajcman H, Tentori L, Labie D. Hemoglobin Maputo: a new beta-chain variant (alpha 2 beta 2 47 (CD6) Asp replaced by Tyr) in combination with hemoglobin S, identified by high performance liquid chromatography (HPLC). *Hemoglobin.* 1983;7(5):423–33. <https://doi.org/10.3109/03630268309038411>. PMID: 6629824.
3. Moo-Penn WF, Hine TK, Johnson MH, Jue DL, Piersma H, Threll Jr B, Chu A. Hb luxembourg [alpha 24(B5)Tyr—His], Hb maputo [beta 47(CD6)Asp—Tyr], and Hb fukuyama [beta 77 (EF1)His—Tyr]. *Hemoglobin.* 1991;15(1–2):97–101. <https://doi.org/10.3109/03630269109072488>. PMID: 1917540.
4. Silva MR, Sendin SM, Araujo IC, Pimentel FS, Viana MB. Clinical and molecular characterization of hemoglobin Maputo [beta 47 (CD6) Asp >Tyr HBB: c.142G >T] and G-Ferrara [beta 57 (E1) Asn >Lys HBB: c.174C >A] in a newborn screening in Brazil. *Int J Lab Hematol.* 2013;35(6):e1–4. <https://doi.org/10.1111/ijlh.12043>. Epub 2012 Dec 27. PMID: 23279838.
5. Sahoo SS, Biswal S, Dixit M. Distinctive mutation spectrum of the HBB gene in an urban eastern Indian population. *Hemoglobin.* 2014;38(1):33–8. <https://doi.org/10.3109/03630269.2013.837394>. Epub 2013 Oct 7. PMID: 24099628.
6. Ibn Ayub M, Moosa MM, Sarwardi G, Khan W, Khan H, Yeasmin S. Mutation analysis of the HBB gene in selected Bangladeshi beta-thalassemic individuals: presence of rare mutations. *Genet Test Mol Biomarkers.* 2010;14(3):299–302. <https://doi.org/10.1089/gtmb.2009.0160>. PMID: 20406103.
7. Wang J, Wang Y, Lv W, Yang L, Huang M, Wang Q. HbA mutation causing false-normal HbA1c results determined by HPLC in a patient with type 2 diabetes mellitus: a case report. *Exp Ther Med.* 2021;22(2):845.. <https://doi.org/10.3892/etm.2021.10277>. Epub 2021 Jun 7. PMID: 34149891; PMCID: PMC8210281.
8. Giambona A, Passarello C, Renda D, Maggio A. The significance of the hemoglobin A(2) value in screening for hemoglobinopathies. *Clin Biochem.* 2009;42(18):1786–96. <https://doi.org/10.1016/j.clinbiochem.2009.06.026>. Epub 2009 Jul 8. PMID: 19591816.
9. Quadros AO, Britto Jr LC. Qualitative analysis of the osmotic fragility test for samples processed fresh or after 24 h of incubation at 370C. *RBAC.* 2021;53(3):245–51. <https://doi.org/10.21877/2448-3877.202101979>.